# A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

> **NCT03983161** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 39 (actual)

## Conditions studied

- Healthy Volunteers
- Hepatic Impairment

## Interventions

- **DRUG:** Fedratinib

## Key facts

- **NCT ID:** NCT03983161
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-04
- **Primary completion:** 2023-01-05
- **Final completion:** 2023-01-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983161, "A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03983161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*